Skip to main
NVAX

Novavax (NVAX) Stock Forecast & Price Target

Novavax (NVAX) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 14%
Hold 14%
Sell 29%
Strong Sell 0%

Bulls say

Novavax is a biotechnology company that has a promising vaccine technology with potential broad application for human infectious diseases and has recently received approval and authorization from the FDA and EC for their COVID-19 vaccine, Nuvaxovid. The company's partnerships and in-house early-stage R&D efforts add value to their pipeline, and positive tolerability data and potential market share for their COVID-19 vaccine could drive financial growth in the future. Risks to consider include potential competition, regulatory uncertainties, and market fluctuations, but the overall outlook for Novavax is positive.

Bears say

Novavax is heavily reliant on its adjuvant technology, Matrix-M, which is still relatively untested and requires further partnerships and clinical trials to establish its efficacy and safety. Additionally, competition in the COVID vaccine market and potential for limited access to booster shots for people without risk factors could limit Novavax's revenue potential.

Novavax (NVAX) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 14% recommend Buy, 14% suggest Holding, 29% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novavax and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novavax (NVAX) Forecast

Analysts have given Novavax (NVAX) a Buy based on their latest research and market trends.

According to 7 analysts, Novavax (NVAX) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novavax (NVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.